Phencyclidine (PCP) induced Schizophrenia Model Development Service

Are you currently facing long drug development cycles and challenges in identifying effective treatments for schizophrenia? Our phencyclidine (PCP)-induced schizophrenia model development services help you accelerate drug discovery by providing a translational platform that accurately models the disease's full symptom spectrum. We achieve this through our advanced preclinical services and state-of-the-art behavioral and cognitive assay platforms.

The PCP-induced schizophrenia model development services provided by Creative Biolabs offer a critical tool for preclinical drug discovery. This service leverages the glutamatergic hypothesis of schizophrenia, which posits that dysfunction of the NMDA receptor system plays a central role in the disease's pathology. The PCP model is a pharmacologically induced animal model that provides a highly translatable platform for evaluating novel therapeutics. It is widely regarded as one of the most reliable animal models for schizophrenia research, particularly for addressing the negative and cognitive symptoms.

How Our PCP-Induced Schizophrenia Model Development Services Can Assist Your Project

Our services are designed to help you de-risk your drug development program by providing a powerful and clinically relevant platform for testing novel therapeutic candidates. We offer specific solutions for addressing the multifaceted pathology of schizophrenia, including the cognitive and negative symptoms that remain a significant unmet need.

Discover How We Can Help - Request a Consultation

Workflow

• Required Starting Materials:

To initiate a project, clients typically provide us with the following:

1. The compound(s) to be tested, including their chemical properties and proposed mechanism of action.
2. A specific research hypothesis or a list of symptoms you aim to target.
3. Relevant background information from your previous in vitro or in vivo studies.

• Final Deliverables:

Upon completion, you will receive:

1. A comprehensive final report detailing the study methodology, results, and conclusions.
2. Raw data files from all behavioral assays and analyses.
3. Expert recommendations for advancing your compound to the next stage of preclinical or clinical development.

• Estimated Timeframe:

The typical timeframe for a standard project ranges from 10 to 14 weeks, but this can vary depending on the complexity of the study design, the number of compounds to be tested, and the scope of the behavioral and molecular analyses required.

Why Choose Us?

Choosing CBL means partnering with a team that has deep expertise in CNS drug discovery and a proven track record of success. Our services are built on a foundation of scientific rigor, flexibility, and a commitment to providing actionable insights that accelerate your research.

Experience the Advantage - Get a Quote Today

Customer Reviews

• "Tangible Benefit" Using CBL's PCP-induced model in our research has significantly improved our ability to screen for compounds that affect cognitive function. The clarity of the data and the detailed reports were instrumental in our decision-making. August 2025, J*** N***
• "Precision and Accuracy" The precision of CBL's behavioral assessments, particularly the social interaction and PPI assays, gave us confidence in our results. Their team's guidance on the nuances of acute versus chronic PCP administration was invaluable. August 2025, M*** T***

Phencyclidine (PCP)-Induced Schizophrenia Model

The PCP-induced schizophrenia model is a gold standard in preclinical research. Unlike models based on dopaminergic stimulants, which only replicate positive symptoms, the PCP model, through its action as a non-competitive NMDA receptor antagonist, reproduces the full spectrum of schizophrenia-like behaviors in rodents. This includes not only positive symptoms like hyperlocomotion and stereotypy but also the key deficits in social interaction and cognitive function that are so difficult to treat. This model's ability to induce neurochemical and neuroanatomical changes, such as cortical connectivity disturbances and reduced spine density, further strengthens its translational validity. The long-lasting effects of subchronic PCP administration on behavior mirror the chronic nature of the human condition, making it a powerful tool for developing next-generation antipsychotics.

Fig.1 PCP induces inhibition of tonic GABA inputs due to the dense distribution of NMDAR on GABA neurons.¹

What We Can Offer

• Customized and Translational Models: Our services provide access to a scientifically validated PCP-induced schizophrenia model that can be tailored to your specific research goals, from acute to subchronic protocols.
• Comprehensive Behavioral Assays: We offer a full battery of advanced behavioral and cognitive tests to evaluate your compound's efficacy against the entire spectrum of symptoms, including those poorly addressed by current treatments.
• Integrated Translational Biomarkers: We can incorporate cutting-edge biomarkers, such as EEG analysis, to establish a direct link between preclinical findings and potential clinical outcomes, accelerating your drug's path to market.
• Expert Project Guidance: Our experienced team provides personalized consultation and scientific support at every step, ensuring your study is meticulously designed and your results are expertly interpreted for maximum impact.
• End-to-End Solution: We offer a seamless workflow from initial consultation and model induction to detailed data analysis, reporting, and optional biochemical and molecular assessments

Related Services

To help you achieve your overall research goals, we offer a range of complementary services that can be integrated with our PCP-induced schizophrenia model development services. These include:

• Target Identification & Validation
• Compound Screening & Profiling
• Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
• Neuroinflammation Research Models

FAQs

Ready to advance your project? Our team of specialists is available to discuss your specific needs and provide a tailored solution.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Li, Dabing et al. "Advances in the study of phencyclidine-induced schizophrenia-like animal models and the underlying neural mechanisms." Schizophrenia (Heidelberg, Germany) vol. 10,1 65. 23 Jul. 2024, doi:10.1038/s41537-024-00485-x. Distributed under Open Access license CC BY 4.0, without modification.